99 related articles for article (PubMed ID: 38538608)
21. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.
Hines MR; Keenan C; Maron Alfaro G; Cheng C; Zhou Y; Sharma A; Hurley C; Nichols KE; Gottschalk S; Triplett BM; Talleur AC
Br J Haematol; 2021 Aug; 194(4):701-707. PubMed ID: 34263927
[TBL] [Abstract][Full Text] [Related]
22. Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells.
Manfredi F; Abbati D; Cianciotti BC; Stasi L; Potenza A; Ruggiero E; Magnani Z; Carnevale E; Doglio M; Noviello M; Tassi E; Balestrieri C; Buonanno S; Clemente F; De Lalla C; Protti MP; Mondino A; Casorati G; Dellabona P; Bonini C
Eur J Immunol; 2021 Aug; 51(8):1992-2005. PubMed ID: 34081326
[TBL] [Abstract][Full Text] [Related]
23. Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation.
Selck C; Dominguez-Villar M
Front Immunol; 2021; 12():661875. PubMed ID: 34054826
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH; Teng YKO; Ginzler EM; Arriens C; Caster DJ; Romero-Diaz J; Gibson K; Kaplan J; Lisk L; Navarra S; Parikh SV; Randhawa S; Solomons N; Huizinga RB
Lancet; 2021 May; 397(10289):2070-2080. PubMed ID: 33971155
[TBL] [Abstract][Full Text] [Related]
25. CAR-T cell therapy: current limitations and potential strategies.
Sterner RC; Sterner RM
Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
[TBL] [Abstract][Full Text] [Related]
26. Deep Phenotyping of CD11c
Rincon-Arevalo H; Wiedemann A; Stefanski AL; Lettau M; Szelinski F; Fuchs S; Frei AP; Steinberg M; Kam-Thong T; Hatje K; Keller B; Warnatz K; Radbruch A; Lino AC; Schrezenmeier E; Dörner T
Front Immunol; 2021; 12():635615. PubMed ID: 33777025
[TBL] [Abstract][Full Text] [Related]
27. Recent advances and discoveries in the mechanisms and functions of CAR T cells.
Larson RC; Maus MV
Nat Rev Cancer; 2021 Mar; 21(3):145-161. PubMed ID: 33483715
[TBL] [Abstract][Full Text] [Related]
28. Pathology of macrophage activation syndrome in humanized NSGS mice.
Tarrant JC; Binder ZA; Bugatti M; Vermi W; van den Oord J; Ranieri B; Assenmacher CA; Hoepp N; O'Rourke DM; Shan X; Danet-Desnoyers G; Radaelli E
Res Vet Sci; 2021 Jan; 134():137-146. PubMed ID: 33383491
[TBL] [Abstract][Full Text] [Related]
29. Development of Mast Cell and Eosinophil Hyperplasia and HLH/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts.
Janke LJ; Imai DM; Tillman H; Doty R; Hoenerhoff MJ; Xu JJ; Freeman ZT; Allen P; Fowlkes NW; Iacobucci I; Dickerson K; Mullighan CG; Vogel P; Rehg JE
Vet Pathol; 2021 Jan; 58(1):181-204. PubMed ID: 33208054
[TBL] [Abstract][Full Text] [Related]
30. Treg Enhancing Therapies to Treat Autoimmune Diseases.
Eggenhuizen PJ; Ng BH; Ooi JD
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977677
[TBL] [Abstract][Full Text] [Related]
31. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells.
Dawson NAJ; Rosado-Sánchez I; Novakovsky GE; Fung VCW; Huang Q; McIver E; Sun G; Gillies J; Speck M; Orban PC; Mojibian M; Levings MK
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32817364
[TBL] [Abstract][Full Text] [Related]
32. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.
Kostopoulou M; Fanouriakis A; Cheema K; Boletis J; Bertsias G; Jayne D; Boumpas DT
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32699043
[TBL] [Abstract][Full Text] [Related]
33. New targets and technologies for CAR-T cells.
Freitag F; Maucher M; Riester Z; Hudecek M
Curr Opin Oncol; 2020 Sep; 32(5):510-517. PubMed ID: 32657796
[TBL] [Abstract][Full Text] [Related]
34. CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD.
Imura Y; Ando M; Kondo T; Ito M; Yoshimura A
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32525846
[TBL] [Abstract][Full Text] [Related]
35. Autoimmunity and organ damage in systemic lupus erythematosus.
Tsokos GC
Nat Immunol; 2020 Jun; 21(6):605-614. PubMed ID: 32367037
[TBL] [Abstract][Full Text] [Related]
36. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Fanouriakis A; Kostopoulou M; Cheema K; Anders HJ; Aringer M; Bajema I; Boletis J; Frangou E; Houssiau FA; Hollis J; Karras A; Marchiori F; Marks SD; Moroni G; Mosca M; Parodis I; Praga M; Schneider M; Smolen JS; Tesar V; Trachana M; van Vollenhoven RF; Voskuyl AE; Teng YKO; van Leew B; Bertsias G; Jayne D; Boumpas DT
Ann Rheum Dis; 2020 Jun; 79(6):713-723. PubMed ID: 32220834
[TBL] [Abstract][Full Text] [Related]
37. Lupus nephritis.
Anders HJ; Saxena R; Zhao MH; Parodis I; Salmon JE; Mohan C
Nat Rev Dis Primers; 2020 Jan; 6(1):7. PubMed ID: 31974366
[TBL] [Abstract][Full Text] [Related]
38. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
[TBL] [Abstract][Full Text] [Related]
39. T
Raffin C; Vo LT; Bluestone JA
Nat Rev Immunol; 2020 Mar; 20(3):158-172. PubMed ID: 31811270
[TBL] [Abstract][Full Text] [Related]
40. Conversion of antigen-specific effector/memory T cells into Foxp3-expressing T
Akamatsu M; Mikami N; Ohkura N; Kawakami R; Kitagawa Y; Sugimoto A; Hirota K; Nakamura N; Ujihara S; Kurosaki T; Hamaguchi H; Harada H; Xia G; Morita Y; Aramori I; Narumiya S; Sakaguchi S
Sci Immunol; 2019 Oct; 4(40):. PubMed ID: 31653719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
